COIOSDeep risk insights through multi-disciplinary research across the globe
A bright stationery store interior with shelves of greeting cards and office supplies
Item new Agency Added

GLP-1 medication use in US adults in 2025, including compounded versions and dose changes

About one in 10 US adults reported past-year GLP-1 use, and 44% of users changed how they took it.

CDC's Rapid Surveys System questioned 8,118 US adults from two probability-based online panels in July–August 2025. Overall, 9.8% reported past-year GLP-1 use, rising from 8.1% with overweight to 24.1% with severe (class 3) obesity. Use was 47.4% among adults who had ever had diabetes, against 5.7% among those who had not. Among the 976 users, 22.6% took a compounded version, more often women (27.3%) than men (14.8%). Some 44% modified prescribed use, mostly by skipping doses (28%), with 54% at ages 18–39 and 30% at ≥65. Cumulative panel response rates were 13.3% and 3.8%, and all data were self-reported.

Why it is interesting: It gives a national survey estimate of GLP-1 uptake, including use of products not reviewed by the FDA. Cost was cited by 58% of modifiers aged 18–39, against 20% of those aged 65 and over.

Source
MMWR. Morbidity and Mortality Weekly Report, 12 November 2026
Paper
Use of Glucagon-Like Peptide-1 Medications and Modified Medication Use Among Adults - United States, 2025
Authors
Pierce SL, Balasuriya L, Kompaniyets L, Goodman AB
DOI
10.15585/mmwr.mm7544a1
Full text
Open copy (open-access copy, PubMed Central)
Type
Agency report
Design
Cross-sectional national survey, CDC Rapid Surveys System, US adults, July–August 2025
Verdict
New finding
Driver
Obesity, diabetes and GLP-1

Other drivers in Health today